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ABSTRACT 
 Background and Aims: Mixing adjuvants with hyperbaric bupivacaine 
in a single syringe before injecting the drugs intrathecally is an age old 
practice. In doing so, the density of the hyperbaric solution and also of the 
adjuvant drugs may be altered, thus affecting the spread of drugs. 
Administering local anaesthetic and the adjuvants separately may 
minimise the effect of the changes in densities. We aimed to compare 
block characteristics, intraoperative haemodynamics and post-operative 
pain relief in parturients undergoing caesarean section (CS) after 
administering hyperbaric bupivacaine and clonidine intrathecally as a 
mixture and sequentially. 
Methods: In this single-blind prospective randomised controlled study at 
a tertiary care centre from 2012 to 2015, 60 full-term parturients 
scheduled for elective caesarean sections  were divided into two groups 
on the basis of technique of intrathecal drug administration. Group M 
received mixture of clonidine (75 mcg) and hyperbaric bupivacaine 0.5% 
(10 mg) intrathecally, whereas Group B received clonidine (75 mcg) 
followed by hyperbaric bupivacaine 0.5% (10 mg) through separate 
syringes. Observational descriptive statistics, independent t test were used 
as applicable. 
 Results: Duration of analgesia was significantly longer in Group B 
(432.60 ± 64.65 min) in which the drug was given sequentially than in 
Group M (322 ± 23.24 min). Furthermore, the time to achieve highest 
sensory block and complete motor block was significantly less in Group 
B without any major hemodynamic instability and neonatal outcome.         
Conclusions: When clonidine and hyperbaric bupivacaine were 
administered in a sequential manner, block characteristics improved 
significantly compared to the administration of the mixture of the two 
drugs. 
Key words: Adjuvants, caesarean section, clonidine, hyperbaric 
bupivacaine, spinal anaesthesia 
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INTRODUCTION   
Neuraxial anaesthesia is now preferred technique for lower 
segment caesarean sections.  Although epidural, spinal, continuous 
spinal and combined spinal epidural techniques have all been 
advocated, most caesarean sections are performed under spinal 
anaesthesia, because of 
1. Greater maternal safety 
2. Less neonatal exposure to potentially depressant 
drugs 
3. Higher patient satisfaction 
4. The option of using spinal adjuvants for 
postoperative pain relief. 
5. Less nausea vomiting 
6. Low risk of mendelson’s syndrome 
7. Less blood loss 
       The choice of local anaesthetic is determined by the intensity of 
motor blockade that is required and the duration of surgery.  In the 
early 1950s lignocaine the first amide local anaesthetic agent came 
into clinical use. Since its introduction into clinical practice 
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lignocaine was extensively used for spinal anaesthesia, but now its 
use has been drastically reduced due to concerns regarding transient 
neurological symptoms.  This prompted search for an alternative 
bupivacaine which  is the first long acting amide local anaesthetic 
agent.  This is the most commonly used long acting amide till now. 
Even when a long acting local anaesthetic like bupivacaine is 
used, the duration of spinal anaesthesia is limited and higher doses of 
analgesics are required in the post-operative period.  Therefore 
achieving a spinal anaesthesia that provides longer duration of 
postoperative analgesia is an attractive goal.  Thus addition of 
adjuvants with hyperbaric bupivacaine has come in to clinical 
practice.  The adjuvants gained widespread popularity as they reduce 
the amount of local anaesthetics and thus the incidence of side 
effects. 
Opioids such as morphine, fentanyl, sufentanyl have been 
administered intrathecally as adjuvants to prolong and potentiate 
post-operative analgesia.  They are associated with many side effects 
like nausea, vomiting, pruritis, urinary retention and late 
unpredictable respiratory depression. 
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Clonidine a selective partial agonist for alpha -2 adrenergic 
receptor is an attractive alternative to commonly used opioids and is 
known to increase both sensory and motor block of local anaesthetics.  
Several studies have shown that clonidine also has 
antihyperalgesic effect and thus reduces postoperative analgesic 
requirement.  Many factors contribute to the spread and action of 
local anaesthetic solution in vivo.  These includes  
1. pH and baricity of the local anaesthetic solution 
2. Temperature of the local anaesthetic solution 
3. Patient position during and after spinal injection 
4. Volume of the drug injected 
5. Height of the patient 
    Commonly adjuvants are mixed with local anaesthetics in 
the single syringe before injecting intrathecally because of its ease of 
administration.  Mixing of these drugs changes the density of both 
drugs, thus affecting their spread in the cerebrospinal fluid (CSF).  
Density is known to influence the spread of local anaesthetics but the 
effect of adjuvant solution density on its movement in the CSF has 
not been studied extensively.  
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Therefore we hypothesized that if we administer local 
anaesthetics and adjutants separately, it may minimize the effect of 
the changes in the densities and also their actions. 
   Therefore we designed the study to compare the efficacy of 
sequential versus premixed administration of clonidine with 
hyperbaric bupivacaine for caesarean sections in terms of block 
charecteristics, intra operative hemodynamics and post-operative pain 
relief. 
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                               AIM OF THE STUDY 
 
  
To compare the efficacy of intrathecal administration of 
hyperbaric bupivacaine and clonidine as a mixture and sequentially in 
lowersegment caesarean section in terms of 
1. Block characteristics 
2. Intraoperative haemodynamics 
3. Postoperative pain relief 
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ANATOMY 
The vertebral canal2 
The spine consists of 33 vertebrae (7 cervical, 12 thoracic, 5 
lumbar, 5 fused sacral, and 4 fused coccygeal), with the exception of 
C1, the cervical, thoracic, and lumbar vertebrae consist of a body 
anteriorly, two pedicles that project posteriorly from the body, and 
two laminae that connect the pedicles.                                                   
These structures form the vertebral canal, which contains the 
spinal cord, spinal nerves, and epidural space. The laminae give rise 
to the transverse processes that project laterally and the spinous 
process that project posteriorly.  
The pedicles contain a superior and inferior vertebral notch 
through which the spinal nerves exit the vertebral canal. The superior 
and inferior articular processes arise at the junction of the lamina and 
pedicles and form joints with the adjoining vertebrae.  
The first cervical vertebra (“atlas”) differs from this typical 
structure in that it does not have a body or a spinous process.  
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The spine of C7 is the first prominent spinous process 
encountered while running the hand down the back of the neck. The 
spine of T1 is the most prominent spinous process and immediately 
follows C7. The 12th thoracic vertebra can be identified by palpating 
the 12th rib and tracing it back to its attachment to T12. A line drawn 
between the iliac crests crosses the body of L5 or the L4-5 inter 
space.  
The spinal cord gives rise to 31 pairs of spinal nerves, each 
composed of an anterior motor root and a posterior sensory root. The 
nerve roots are in turn composed of multiple rootlets. The portion of 
the spinal cord that gives rise to all of the rootlets of a single spinal 
nerve is called a cord segment.  
The skin area innervated by a given spinal nerve and its 
corresponding cord segment is called a dermatome.  
Because the spinal cord usually ends between L1 and L2, the 
thoracic, lumbar, and sacral nerve roots run increasingly longer 
distances in the subarachnoid space to get from their spinal cord 
segment of origin to the intervertebral foramen through which they 
exit. Those nerves that extend beyond the end of the spinal cord to 
their exit site are collectively known as the cauda equina.  
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Ligaments of vertebral column3 
1)Supraspinous ligament 
               It is a strong, thick, fibrous band, connecting the apices of 
the spines from the seventh cervical vertebra to the sacrum. At the 
lumbar region it is thick and broad. In the cervical region it blends 
with neck ligaments.  
2)Interspinous ligament 
            The interspinous ligament is a thin fibrous structure, 
connecting adjacent spines. The fibres are almost membranous and 
extend from the apex and upper surface of a lower spine towards the 
root and inferior surface of the next higher vertebra. These 
longitudinal fibres meet the supraspinous ligament posteriorly and 
tends to blend with the ligamentum flavum in front.  
3)Ligamentum flavum 
            This consists of yellow elastic tissue. They extend between 
lamina from the anterior inferior surface of the upper lamina 
downwards to the anterior superior surface of the lower lamina. The 
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ligament thickness, distance to dura, and skin to dura distance vary 
with the area of vertebral canal. 
Characteristics of ligamentum flavum at different vertebral level, site  
Thickness of ligament (mm)  
Cervical 1.5-3.0  
Thoracic 3.0-5.0  
Lumbar 5.0-6.0  
Caudal 2.0-6.0  
4)Posterior longitudinal ligament: 
 It extends along the posterior surfaces of vertebral bodies from 
which it is separated by the basivertebral veins              
5)Anterior longitudinal ligament:                                         
It runs along the anterior surface of vertebral bodies from C2 to   
sacrum.                                                                                              
Anatomy of the spinal cord3        
           At birth, the tip of the spinal cord lies at the level of the lower 
border of L3 and the dural sac at the third sacral vertebrae. After 
birth, the lengthening and growth of the cord, as well as the 
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meninges, continue to lag behind the growth of the bony vertebral 
column. At one year of age, the conus medullaris reaches the lower 
border of the second lumbar vertebra and the dural sac ends at the 
second sacral vertebra. This differential growth rate results in the 
development of the epidural space and the caudal canal.  
Between 12-16 years of age, the adult relations are attained, 
and the spinal cord is located at the lower border of the 1st lumbar 
vertebrae. This placement is seen in 50% of patient and in about 40% 
it is located opposite the body of second lumbar vertebrae.  
The average length of the spinal cord in males is about 45 cms, 
and in females it is about 42 centimetres. The average weight is 
approximately 30 grams.  
Meningeal coverings of the spinal cord1,3 
Surrounding the spinal cord in the bony vertebral column are 
three membranes (from within to the periphery): the pia mater, 
arachnoid mater and dura mater. 
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Dura mater 
             This layer is the direct extension of the cranial dura mater 
and extends as spinal dura mater from the foramen magnum to S2, 
where the filum terminale blends with the periosteum on the coccyx.  
 
Arachnoid mater  
        This is the middle of the three coverings of the brain and spinal 
cord. It is a delicate non-vascular membrane closely attached to the 
dura and ends at the lower border of S2.        
Pia mater  
            This is a delicate, highly vascular membrane, closely 
investing the spinal cord and brain. Denticulate ligaments are the 
folds of pia mater that extends laterally along the lines of attachments 
of the anterior and posterior roots. They act as struts to hold the 
spinal cord suspended within the subdural space.  
Dural spaces1 
In the subarachnoid space are the CSF, spinal nerves and blood 
vessels that supply the spinal cord and the lateral extensions of the 
pia mater and the dentate ligaments, which supply lateral support 
from the spinal cord to the dura mater.  
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Although the spinal cord ends at the lower border of L1 in 
adults, the subarachnoid space continues to S2. There is a potential 
space between the dura mater and the arachnoid, the subdural space, 
which contains only small amounts of serous fluid allowing the dura 
and arachnoid to move over each other.  
Surrounding the dura mater is the spinal epidural space extends 
from the foramen magnum to the sacral hiatus. The epidural space is 
bounded anteriorly by the posterior longitudinal ligaments, laterally 
by the pedicles and the intervertebral foramina, and posteriorly by the 
ligamentum flavum.  
Contents of the epidural space include the nerve roots that 
traverse it from foramina to peripheral locations, as well as fat, 
areolar tissue, lymphatics, and blood vessels which include the well-
organized Batson venous plexus. 
Circulation of the Spinal Cord3 
Arterial supply to the Spinal Cord  
           The principal arterial supply to the spinal cord is derived from 
one anterior and two pairs of posterior spinal arteries that descend 
from the level of the foramen magnum.  
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            The anterior spinal artery is formed at the foramen magnum 
by a branch from the terminal portion of each vertebral artery. This is 
a large artery and lies in the midline on the anterior median fissure. It 
descends the entire length of the spinal cord and with contributing 
arteries, supplies a major portion of the anterior two-thirds of the 
spinal cord.  
         The posterior spinal arteries are four longitudinal running 
vessels, two on each side. One lies in front of the attachment of the 
dorsal nerve root, and the other or larger artery lies behind the 
attachment. These arteries are derived at the base of the brain, either 
directly from the vertebral artery or more often from a primary 
branch of the posterior inferior cerebellar artery, the largest branch of 
each vertebral artery. They supply the posterior one third of the spinal 
cord, i.e., the posterior gray horns and white columns.  
Reinforcement of Arterial Supply  
           Contributing by anastomotic channels to the anterior and 
posterior spinal cord arteries are a succession of spinal radicular 
branches arising from local segmental arteries (derived from the 
aorta) of the vertebral, ascending cervical, posterior intercostal, spinal 
lumbar and lateral sacral arteries. Each spinal branch divides into an 
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anterior radicular and posterior radicular artery that approaches the 
spinal cord along the ventral and dorsal roots 
           Most of the anterior radicular arteries are small and terminate 
within the ventral nerve roots or in plexus of the pia around the cord. 
Frequently, one of these anterior radicular arteries is considerably 
larger than all the others and is termed the arteria radicularis magna, 
or the artery of Adamkiewicz. It arises from one of the intersegmental 
branches of the descending aorta at the lower thoracic or upper 
lumbar vertebral level usually on the left side (80%). This radicular 
artery may be responsible for the major blood supply of the lower 
two-thirds of the spinal cord in about 50% of the population.  
            The arterial supply to the spinal cord is a delicate system and 
is quite vulnerable to minor trauma and to vasoconstrictor drugs. 
Occlusion of the anterior spinal artery produces the anterior spinal 
artery syndrome denoted by lower limb paralysis without loss of 
posterior column sensation, i.e, touch, position, vibratory, and joint 
senses, or cauda equina syndrome denoted by sphincter disturbances.  
Veins of the spinal cord  
           The veins of the spinal cord are situated in the pia mater. They 
are six in number and form longitudinal plexiform channels after 
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draining the parenchyma of the cord. In this plexus, there are (1) two 
median longitudinal veins, one anterior in the anterior fissure, and the 
other posterior at the posterior sulcus of the cord, and (2) four lateral 
longitudinal veins: one pair (posteriolateral) runs dorsal to the 
attachment of the nerve roots and the other pair ventral to the nerve 
roots (anterolateral). These veins communicate with the internal 
vertebral plexus, from which blood drains into the intervertebral 
veins. The intervertebral veins pass out through the intervertebral 
foramina to the segmental veins and to the external vertebral plexus. 
Cerebrospinal fluid (CSF) 2:  
The term cerebrospinal fluid was first used in 1825 by French 
Physiologist F.Magendie. It is normally clear & colorless fluid that 
fills all the cavities and space around the central nervous system. It is 
isotonic with plasma. It is secreted mainly by choroid plexus of 
lateral ventricle and is reabsorbed by the arachnoid villi and 
granulations.  
In a normal adult, cerebrospinal fluid is formed at a rate of 25 
ml/hr or 600 ml/day. The replacement of total spinal fluid under 
ordinary normal physiological circumstances is every 6 hours. 
Cerebrospinal fluid is a complex solution containing an array of 
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molecules including electrolytes, proteins, glucose, neurotransmitters, 
neurotransmitter metabolites, cyclic nucleotides, amino acids, among 
many others. Cerebrospinal fluid is produced by ultra filtration of 
plasma in the choroid plexus and the cerebral/spinal capillaries and 
by oxidation of glucose, which produces water as a “by-product”. 
The cerebrospinal fluid volume is approximately 100 to 160 ml in 
adult humans and it is produced at the rate of 20 to 25 ml/hr. 
Consequently, the entire cerebrospinal volume is replaced roughly 
every 6 hours.  
Cerebrospinal fluid is removed by arachnoid villi present in the 
superior sagittal sinus and along many spinal nerve roots.  
Baricity is defined as the ratio of the density (mass/volume) of 
the local anaesthetic solution divided by the density of cerebrospinal 
fluid, which averages 1.0003±0.0003 g/ml at 37°C. Solutions that 
have the same density as cerebrospinal fluid  have a baricity of 
1.0000 and are termed isobaric. Solutions that are denser than CSF 
are termed hyperbaric, whereas solutions that are less dense than CSF 
are termed hypobaric.  
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Baricity is important in determining local anesthetic spread and 
thus block height because gravity causes hyperbaric solutions to flow 
downward in CSF to the most dependent regions of the spinal 
column, whereas hypobaric solutions tend to rise in CSF. In contrast, 
gravity has no effect on the distribution of truly isobaric solutions. 
Thus, the anaesthesiologist can exert considerable influence on block 
height by choice of anaesthetic solution and proper patient 
positioning. 
Characteristics of CSF 
                    Specific gravity at 37°C 1.006 (1.003-1.009)  
Volume 130-150 mL  
Vol. in subarachnoid space 25 – 35 mL  
Pressure 70-180 mm of water  
Circulation 
             From the lateral ventricles cerebrospinal fluid  passes through 
the foramina of Munro to the third ventricles, then through the 
aqueduct of sylvius to the fourth ventricle and then via foramen of 
Magendie to cisterna magna and via two foramen of Luschka into 
cisterna ponti. From the fourth ventricles it also passes into central 
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canal of spinal cord. From the central subarachnoid space, it reaches 
spinal subarachnoid space through the foramen magnum 
cerebrospinal fluid is absorbed into cranial venous sinuses through 
arachnoid villi.  
 
Functions of CSF 
1.  It acts as cushion between the soft and delicate brain substance 
and rigid cranium. 
2.  Drainage of metabolites  
 3.  Nutrition and oxygen supply to nerve cells to some extent.  
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PHYSIOLOGY OF CENTRAL NEURAXIAL 
BLOCKADE4,5,6,7,8,9,10 
 The well recognized physiological effects of subarachnoid 
block are often mistakenly termed as complications. It is imperative 
to make a clear distinction between the physiologic effects of an 
anaesthetic technique and complications that implies some harm to 
the patients.  
The various factors7,8 which affect the spread of local 
anaesthetics include, 
       Patient factors:  
1. Age  
2. Height  
3. Position  
4. Spinal column configuration  
5. CSF volume  
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Technical factors:  
1. Site of injection  
2. Spread of injection  
3. Direction of needle  
4. Local anesthetic dose  
5. Local anesthetic baricity  
6. Local anesthetic volume  
Factors not affecting the spread of local anaesthetic in the sub 
arachnoid space:  
1. Weight of patient  
2. Local anesthetic concentration  
3. CSF composition  
4. CSF circulation  
5. Vasoconstrictors  
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Amount of drug 
With greater amounts of drug there is an increase in the 
duration, height and intensity of spinal anaesthesia. There is an upper 
limit to the total amount of agent that may be used regardless of the 
volume and it is determined by the amount of that drug which may 
produce neurological damage.  
.Volume of solution 
If the amount of drug is maintained same, increasing the volume may 
increase the extent of anaesthesia. If the total volume is small the 
effect of volume augmentation is limited.  
Site of injection 
Selection of one or two spaces higher than usual L3-L4 
interspace provides a higher level of anaesthesia when all other 
conditions are constant.  
Rate of injection 
This is perhaps the most important factor in determining the 
height of anaesthesia. With slow injections, the levels are low. Very 
rapid injections may cause anaesthesia to reach well into the thoracic 
area. Rate of injection 0.2ml/sec. 
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Barbottage 
The term is derived from the French word 'barboter'- to puddle 
or mix. This is the technique of stirring up to increase turbulence, 
mixing of injected solution and increasing distribution in the sub 
arachnoid block. The to and fro movement agitates the injectate in the 
spinal fluid and mixes the agent more completely and carry the agent 
more extensively to higher levels.  
Specific gravity, density and baricity 
When hyperbaric solutions are used with patient supine in 
horizontal plane the anaesthetic will preferentially travel to the low 
points of sub arachnoid space i.e., below L3 into the lumbosacral 
concavity. Hyperbaric solutions travel to the most dependent part of 
the subarachnoid space when there are deviations of the patient’s 
position from the horizontal. Isobaric solutions are considered not to 
spread with changes in position and the levels of anaesthesia are 
independent of positioning. The solution puddles near the site of 
injection.  
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Hypobaric solutions in contrast to hyperbaric solutions are not 
influenced by gravity and position of patient. They are administered 
while patient is in prone position.  
Pharmacokinetics of spinal anaesthesia 
There is a fall in the concentration soon following the injection 
of anaesthetic agent into the subarachnoid space. The reason being,  
1. Dilution and mixing of CSF  
2. Diffusion and distribution to neural tissues  
3. Uptake and fixation by neural tissues  
4. Vascular absorption and elimination  
5. Through arachnoid villi  
Initially, there is a rapid decrease in the concentration of drug, 
which occurs within 2-3 min soon after the injection of drug. This is 
due to mixing and dilution with CSF, which depends on the force or 
rate of injection of drug and amount or volume of fluid in the 
subarachnoid space.  
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The second phase of decrease in concentration is due to 
diffusion of agent in the spinal fluid by virtue of its molecular 
motion.  
At the same time some of the agent is being absorbed into the 
nervous tissue.  
This absorption occurs along a concentration gradient to 3 sites:  
           1. The nerve roots directly bathed by the anaesthetics. 
2. Directly into the spinal cord surface by diffusion through the 
piamater. 
3. Into the deeper parts of the spinal cord parenchyma through 
Virchow-Robin spaces. 
Uptake of local anaesthetic from the spinal fluid and from the 
nerve fibres into the vascular compartment accounts for the third 
phase of slow decrease in total concentration of agent in the spinal 
fluid. The greater portion of the drug leaves the subarachnoid space 
through the venous drainage, while a small portion leaves through 
small lymphatic channels. Little or no breakdown of local anaesthetic 
agents occurs in the subarachnoid space or in the CSF.  
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The sequence of nerve modality block9 
1. Vaso motor block – dilatation of skin vessels and 
increased cutaneous blood flow. 
2. Temperature fibres – cold first and then warmth  
3. Loss of temperature discrimination  
4. Pain – pin prick fibres first 
5. Loss of tactile sensation  
6. Motor paralysis  
7. Pressure sensation  
8. Proprioception and vibratory sensation  
The recovery, return of sensibility is in the reverse order. 
Sympathetic blockade is the major determinant of physiologic 
response to spinal anaesthesia. Indirect effects of spinal anaesthesia 
may be considered as a result of paralysis of these nerves.  
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Effect of Spinal Anaesthesia on Various Organs10 
Cardiovascular System 
Cardiovascular changes are the most important physiologic 
response to spinal anaesthesia. They are mediated by combined 
autonomic denervation and higher levels of neural blockade and 
uninhibited vagal activity. 
Sympathetic Denervation 
The level of sympathetic blockade determines the magnitude of 
cardiovascular responses to spinal anaesthesia. Higher the level of 
neural blockade the greater would be the  changes in cardiac and 
circulatory parameters. In the presence of partial sympathetic 
blockade a reflex increase in sympathetic activity occurs in 
sympathetically intact areas. The result is vasoconstriction that tends 
to compensate for peripheral vasodilatation taking place in 
sympathetically denervated areas. 
Arterial Circulation 
Sympathetic denervation produces arteriolar vasodilatation, 
relaxation of vascular smooth muscles on the arterial side of 
circulation. As a result of this total peripheral vascular resistance 
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decreases about 15% to 18% in normal subjects in the presence of 
total sympathetic denervation provided the cardiac output and other 
determinants of blood pressure are kept normal.  
Venous Circulation 
Veins and venules with only few smooth muscles on their 
walls have no significant residual tone. Hence following 
pharmacological denervation, no significant change. They can 
vasodilate maximally. This is determined by intraluminal hydrostatic 
pressure.  
Intraluminal hydrostatic pressure on the venous sides of the 
circulation depends on the gravity. If the denervated veins lie above 
the level of right atrium, it causes the blood flow back to the heart. 
Preload to the heart therefore depends on the position of the patient 
during spinal anaesthesia.  
Heart Rate 
Spinal Anaesthesia is characteristically associated with slowing 
of the heart rate. The degree of bradycardia as well as the frequency 
with which it occurs can be roughly correlated with the extent of 
sympathetic denervation.  
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Pronounced bradycardia is observed most frequently when 
cardiac output and arterial blood pressures have decreased 
significantly. 
 Cerebral Blood Flow 
Cerebral blood flow is governed by two main factors. Mean 
arterial blood pressure and local resistance to blood flow in cerebral 
vessels. Spinal anaesthesia theoretically could influence cerebral 
blood flow altering either blood pressure or cerebrovascular 
resistance or both. Cerebrovascular auto regulatory mechanism 
maintains cerebral blood flow in humans at constant levels in the 
presence of wide fluctuations in mean arterial blood pressure.  
Cerebral blood flow will become pressure dependent until the 
mean arterial pressure (MAP) falls below 55 mm Hg. 
Cerebrovascular auto regulation is independent of the sympathetic 
nervous system. Cerebral blood flow remains unaffected in normal 
persons even when mean arterial pressure decreases from 90 to 60 
mm Hg during spinal anaesthesia.  
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The respiratory system 
The phrenic nerve supplying the diaphragm arises from the 
anterior roots of C3-C5 and should not be encroached on in spinal 
analgesia, but phrenic paralysis can occur. Apnea may be due to 
medullary ischemia or due to toxic effects of the drug in extradural 
blocks. During spinal analgesia breathing becomes quiet and tranquil. 
This is not only due to motor blockade but also due to 
deafferentiation with reduction of sensory input to the respiratory 
centre.  
Lowered arterial and venous tone also lessens the work of the 
heart and tends to relive any existing pulmonary congestion. The 
ventilation perfusion relationship during extradural block is not 
greatly altered and the effect on respiratory function is relatively 
small with no evidence of change in functional residual capacity or 
V/Q ratio. The pulmonary gas-exchange is preserved. Intercostal 
paralysis is compensated for by increased descent of the diaphragm, 
which is made easier by a lax abdomen  
 
 
 
30 
 
The gastrointestinal system 
Pre-ganglionic sympathetic fibres from T5-Ll are inhibitory to 
the gut. There is no effect on oesophagus, the innervation of which is 
vagal. The small gut is contracted as sympathetic inhibitory impulses 
are removed, the vagus being all-powerful. The sphincters are relaxed 
and peristalsis is active although not more frequent. Pressure within 
the bowel lumen is increased. Handling of small bowel by the 
surgeon may cause it to dilate, as may the injection of atropine before 
the operation. Nausea and vomiting due to the hypotension may occur 
and usually comes on in waves lasting a minute or so and passes 
away spontaneously.  
 
The Spleen  
The spleen enlarges 2-3 times in high blocks when its 
sympathetic efferent fibres are paralyzed. Colonic blood supply and 
oxygen availability are increased in animals following spinal 
analgesia, perhaps an important factor in the prevention of 
anastamotic breakdown following gut resection.  
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The liver 
 The degree of hypotension, which compromises liver function, 
is not known. If the liver is diseased, a decrease in the mean arterial 
pressure affects the liver blood flow and also the metabolism of 
amide anaesthetics. 
Endocrine system 
Spinal block delays adrenal responses to injury and trauma, so 
there is no change in the levels of 17- hydroxy corticosteroids. Spinal 
block suppresses the hyperglycemic response to surgery and stress 
and so is useful in diabetic patients. The response to insulin is 
augmented, one should be aware of possibility of hypoglycaemia. 
Infused glucose through intravenous route is well utilized. 
Genitourinary system 
Sympathetic supply to kidney is from T11-L1 via the lower 
splanchnic nerve. Any effects on renal function are solely due to 
hypotension, renal blood flow is decreased but does not cease until 
blood pressure has fallen to about 80mm Hg. These changes are 
transient and disappear when blood pressure rises again. The penis is 
often engorged and flaccid due to paralysis of Nervi erigenti (S2-S3) 
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and this is also a positive sign of a successful block. Post spinal 
retention of urine may be moderately prolonged as S2-S3 contains 
small autonomic fibres and their paralysis lasts longer that of larger 
sensory and motor fibres. During prolonged blockade of lumbar and 
sacral segments, the bladder must be palpated so that catheterization 
can be employed when necessary. Spermatorrhoea is sometimes seen.  
Uterus 
The tone of uterus is not greatly altered after spinal analgesia 
in pregnancy. Blockade of nerves from T11 downwards results in 
painless labour. In late pregnancy, smaller doses of local anaesthetics 
are required because of decreased extradural space.  
 
Body temperature 
Vasodilatation favours heat loss, absence of sweating favours 
hyperpyrexia in hot environment, catecholamine secretion is 
depressed hence heat loss is produced by metabolism.  
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         PHARMACOLOGY OF CLONIDINE11,12,13,14,15,16,17 
 
Clonidine, an Imidazoline derivative, was synthesized in the 
early 1960s and was found to produce vasoconstriction which was 
mediated by alpha receptors. 
CHEMISTRY 
C9H9N3Cl2.HCl 
2,6-Dichloro-N-2-
imidazolidinylidenebenzaminehydrochloride. 
                          
 PHARMACOLOGY 
The α2-Adrenergic receptor 
Clonidine is a partial agonist at alpha adrenoceptors both 
within the central nervous system and in the periphery. It is more 
specific for alpha 2-adrenoceptors than for alpha 1-adrenoceptors 
with a ratio of affinities at these sites of approximately 200:1. Within 
the central nervous system alpha 2-adrenoceptors are located both 
presynaptically on terminals of neurons which release a variety of 
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transmitters norepinephrine, epinephrine, serotonin and acetylcholine, 
and postsynaptically on nor-adrenergic neurons. It is likely that 
clonidine acts at all central alpha 2-receptors, stimulation of which is 
associated with decreased neuronal excitability and inhibition of 
membrane bound adenylate cyclase. 
  
High concentrations of clonidine may stimulate central alpha1 
adrenoceptors enhancing neuronal excitability. Stimulation of 
peripheral presynaptic a2-adrenoceptors on post ganglionic 
noradrenergic or cholinergic neurons by clonidine contributes to 
reduced saliva flow, reduced intestinal motor activity and gastric acid 
secretion, and bradycardia. 
Endocrine and metabolic effects apparently mediated by alph2 
adrenoceptor stimulation are, increased TSH and GH secretion, 
decreased ACTH and ADH secretion, and inhibition of glucose-
stimulated insulin release. Clonidine inhibits insulin secretion from 
the pancreatic R cell possibly via an alpha 2 receptor. An alternative 
explanation is that this action is mediated via an Imidazoline receptor. 
The pressor effect of high doses of clonidine is due to peripheral 
vasoconstriction mediated by stimulation of postsynaptic alpha 1 and 
alpha 2  adrenoceptors on vascular smooth muscle. 
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Questions remain about whether the sympatho-inhibitory 
action of clonidine results solely from its a2-receptor agonism or 
whether part or all of its actions are mediated by Imidazoline 
receptors. 
 
The Imidazoline receptor 
          Imidazoline receptors include three subtypes (I1, I2 and I3), and 
are widely distributed in the body, including the CNS. Clonidine, as 
an imidazoline binds to these imidazoline receptors, in addition to its 
well-described binding to alpha2 receptors. Data suggest that 
imidazoline receptors make only a minor contribution to the ability of 
clonidine to inhibit norepinephrine release, while the main 
contribution to the action of clonidine is via α2-receptors. 
 
PHARMACOLOGICAL ACTIONS 
CARDIOVASCULAR ACTIONS 
The major pharmacological effects of clonidine involve 
changes in blood pressure and heart rate, although the drug has a 
variety of other important actions. Intravenous infusions of clonidine 
cause an acute rise in blood pressure, apparently because of the 
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activation of post synaptic α2- receptors in vascular smooth muscle.  
Oral or intravenous administration of clonidine causes a dose-
dependent fall in blood pressure and heart rate in both the supine and 
erect positions, with the orthostatic response being more prominent 
that are not seen in patient taking clonidine chronically.  
The hypertensive response preceding the hypotensive effect 
following acute intravenous administration of clonidine, generally is 
not seen with oral administration. However, even after intravenous 
administration, the transient vasoconstriction is followed by a more 
prolonged hypotensive response that results from decreased 
sympathetic outflow from the CNS. 
 
The blood pressure lowering effect appears to result, at least in 
part from activation of α2 receptors in the lower brainstem region. 
 
ENDOCRINE AND METABOLIC EFFECTS 
In patients with the usual low fasting plasma growth hormone 
(GH) concentrations, clonidine acutely increases plasma GH 
concentrations (mean 10-20 fold) and chronically may be associated 
with increases of variable magnitude in basal GH concentrations. 
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With high basal GH concentrations, clonidine acutely and chronically 
decreases HGH concentration.  
 
Acute and chronic administration of clonidine reduces plasma 
ACTH and cortisol concentrations. There is no effect on the plasma 
concentrations of prolactin, FSH, or LH. Clonidine also causes a 
small rise in blood glucose and a fall in plasma insulin in normal 
persons. Both effects are inhibited by the peripheral a2-antagonist 
MK – 467. 
 
The effects of clonidine on carbohydrate metabolism appears 
to be variable. Some studies suggest that clonidine does not affect 
carbohydrate metabolism in diabetic or non-diabetic hypertensive 
patients, although there has been a report of a diabetic patient in 
whom clonidine was associated with elevated fasting blood-glucose 
values, and increased insulin requirements were noted in a diabetic 
child treated with clonidine for tics. Conversely, clonidine was 
associated with severe hypoglycemia in children when used as a 
provocative test for growth hormone deficiency. Studies have shown 
that clonidine administration in animals and man causes slight 
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hyperglycemia, lipid mobilization and increase in growth hormone 
levels. 
 
Clonidine induced defective insulin secretion and impaired 
glucose tolerance by selective stimulation of a-adrenergic pathways. 
This induction of hyperglycemia by clonidine was reversed by 
infusions of the a-adrenergic blocking agent phentolamine and in the 
presence of a-blockade; clonidine had no effect on plasma glucose. 
  
Clonidine was reported to decrease glucose tolerance in 
maturity onset diabetics without any significant effect on glycemic 
control, and clonidine was also shown to favourably alter lipid 
profile. Clonidine appears to be promising in diabetic hypertensive 
patients, but more studies are warranted due to paucity of data on its 
lipid effects. 
 
ACTIONS ON GASTROINTESTINAL TRACT 
Clonidine may stimulate α2-adrenoceptors on enterocytes thus 
promoting fluid and electrolyte absorption and inhibiting anion 
secretion. It may also modify intestinal motility and rectal sphincter 
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tone. Because of these antidiarrhoeal properties, clonidine has been 
found to be of benefit in diabetic diarrhoea. 
 
PHARMACOKINETICS 
Clonidine is well absorbed after oral administration, and its 
bioavailability is nearly 100%, with peak concentrations in plasma 
and the maximal hypotensive effect being observed 1 to 3 hours after 
an oral dose. The elimination half-life of the drug ranges from 6 to 24 
hours, with a mean of about 12 hours. Approximately half of the 
administered dose can be recovered unchanged in urine, and the half-
life of the drug may increase with renal failure. There is good 
correlation between plasma concentrations of clonidine and its 
pharmacological effects. A transdermal delivery patch, an alternative 
to oral therapy permits continuous administration of clonidine. The 
drug is released at an approximately constant rate for a week, 
requiring 3 or 4 days to reach steady-state concentrations in plasma.  
When the patch is removed, plasma concentration remain 
stable for about 8 hours and then decline gradually over a period of 
several days, this decrease in concentration is associated with a rise in 
blood pressure. Clonidine crosses the placenta and is distributed into 
breast milk. 
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ADVERSE EFFECTS 
The major adverse effects of clonidine are dry mouth and 
sedation occurring in at least 50% of patients and may require drug 
discontinuation. However, they may diminish in intensity after 
several weeks of therapy. Sexual dysfunction may also occur. 
Constipation is also common. Marked bradycardia is observed in 
some patients. These and some of the other adverse effects of 
clonidine are related to dose, and their incidence may be lower with 
transdermal administration of clonidine. 
 
Other adverse effects which have been reported include 
depression, anxiety, fatigue, nausea, anorexia, parotid pain, sleep 
disturbances, vivid dreams, impotence and loss of libido, urinary 
retention or incontinence, slight orthostatic hypotension, and dry, 
itching or burning sensation in the eye. Transient fluid retention may 
be responsible for a reduction in hypotensive effect during continued 
treatment. 
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About 15 to 20% of patients develop contact dermatitis, rashes 
and pruritus with the use of transdermal delivery systems. Less 
frequently, bradycardia, including sinus bradycardia with 
atrioventricular block, other ECG disturbances, heart failure, 
hallucinations, cramp, Raynaud’s syndrome, gynaecomastia, and 
transient abnormalities in liver function tests has been reported. 
Symptoms of over dosage include transient hypertension or profound 
hypotension, bradycardia, sedation, miosis, respiratory depression, 
convulsions, and coma. 
 
Sudden withdrawal of clonidine may produce rebound 
hypertension i.e., withdrawal reactions follow abrupt discontinuation 
of long-term therapy with clonidine in some hypertensive patients. 
No teratogenicity, mutagenicity or carcinogenicity have been 
demonstrated with clonidine. 
 
CONTRAINDICATIONS 
Disorders of cardiac pacemaker activity and conduction. 
Sino-atrial node disease (Sick sinus syndrome) 
Atrioventricular node disease. 
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THERAPEUTIC USES 
1. In hypertension 
2. Anxiety disorders 
3. Glaucoma 
4. Psychiatric disorders 
5. Diarrhoea 
6. Cardiac arrhythmias 
7. Extrapyramidal disorders 
8. Growth retardation 
9. Menopausal disorders 
10. Orthostatic hypotension 
11. Migraine 
12. Premedication 
13. Phaeochromocytoma 
14. Shivering 
15. Spasticity 
16. Cyclosporine associated nephrotoxicity  
17. Post herpetic neuralgia 
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ROUTES OF ADMINISTRATION 
1. Oral tablets 
2. Transdermal patch 
3. Intrathecal/epidural and intravenous injection 
4. Intra Venous Regional Anesthesia 
5. Plexus Block 
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                      PHARMACOLOGY OF BUPIVACAINE15,16,17 
 
Bupivacaine, an amino amide local anaesthetic was first 
synthesized in Sweden by A.F Ekenstam and his colleagues in 1957. 
First report of its use was in 1963 by L.J Teluvio. It is one of the long 
acting local anaesthetic agents available, which is extensively used 
for intrathecal, extradural and peripheral nerve blocks. It is a white 
crystalline powder soluble in water 
  
CHEMICAL STRUCTURE OF BUPIVACAINE 
                               
Bupivacaine has an IUPAC nomenclature of 1-butyl-n-(2,6- 
dimethylphenyl) piperidine-2-carboxamide. 
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Physiochemical properties18 
Molecular formula   : C18 H28 N2O HCl 
Molecular weight   : 288.43 g/mol 
Solubility in water   : 25mg/ml 
pH of saturated solution  : 5.2 
pKa     : 8.1 
Specific gravity   : 1.021 at c37 °C 
Melting point   : 247 - 258°C 
  
Mechanism of action19,20 
Mechanism of action of bupivacaine is similar to that of any 
other local anaesthetic. The primary action of local anaesthetics is on 
the cell membrane of the axons, on which it produces electrical 
stabilization. Bupivacaine prevents transmission of nerve impulses 
(conduction blockade) by inhibiting passage of sodium ions through 
ion-selective sodium channels in nerve membranes.  
The sodium channel is a specific receptor for local anaesthetic 
molecules. The local anaesthetics block the nerve conduction by 
decreasing the entry of sodium ions during upstroke of action 
potential.  
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As the concentration of the local anaesthetic is increased, the 
rate of rise of action potential and maximum depolarisation decreases 
causing slowing of conduction. Finally local depolarization fails to 
reach the threshold potential and conduction block ensues. 
 
The mechanism by which local anaesthetics block sodium 
conductance is as follows 
        1) Local anaesthetics in the cationic form act on the receptors 
within the sodium channels on cell membrane and block it. The local 
anaesthetics can reach the sodium channel either via the lipophilic 
pathway directly across the lipid membrane, or via the axoplasmic 
opening. This mechanism accounts for 90% of the nerve blocking 
effects of amide local anaesthetics. 
       2) The second mechanism of action is by membrane expansion. 
This is a nonspecific drug receptor interaction. 
Other site of action targets 
• Voltage dependent potassium ion channels 
• Calcium ion currents (L-type most sensitive) 
• G protein coupled receptors 
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 Dosage depends on 
 Area to be anaesthetized 
 Number of nerve segments to be blocked 
 Individual tolerance 
          Technique of local anaesthesia 
         Vascularity of area 
 
Bupivacaine is available in the following concentrations 
 0.25%. 0.5%and 1% 
 0.25% and 0.5% solution in isotonic saline 
 0.5% solution in 8% dextrose 
 
ANESTHETIC POTENCY 
Hydrophobicity appears to be a primary determinant of 
intrinsic anesthetic potency and Bupivacaine is highly hydrophobic, 
hence is very potent. 
ONSET OF ACTION 
The onset of conduction blockade is dependent on the dose or 
concentration of the local anesthetic. The onset of action of 
bupivacaine is between 4 – 6 minutes and maximum anaesthesia is 
obtained between 15 – 20 minutes. 
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DURATION OF BLOCK 
The duration of anesthesia varies according to the type of 
block; the average duration of peridural block is about 3.5 – 5 hours, 
for nerve blocks, it is about 5 – 6 hours. 
 
PHARMACOKINETICS 
The rate of systemic absorption of local anaesthetics is 
dependent upon the total dose and concentration of drug 
administered, the route of administration, the vascularity of the 
administration site, and the presence or absence of epinephrine in the 
anaesthetic solution. A dilute concentration of epinephrine (1:200,000 
or 5 mcg/ml) usually reduces the rate of absorption and peak plasma 
concentration of bupivacaine, permitting the use of moderately larger 
total doses and sometimes prolonging the duration of action. 
 
Plasma binding  
In plasma, drug binds avidly with protein to the extent of 70 -
90%. The rank order of protein binding for this and its homologues is 
bupivacaine > mepivacaine > lidocaine. Conversely, the unbound 
active fraction is one seventh of lidocaine and one fifth of 
mepivacaine. 
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Absorption 
The site of injection, dose and addition of a vasoconstrictor 
determine the systemic absorption of Bupivacaine .The maximum 
blood level of bupivacaine is related to the total dose of drug 
administered from any particular site. Absorption is faster in areas of 
high Vascularity. 
 
Toxicity 
The toxic plasma concentration is set at 4 - 5 µg/ml. maximum 
plasma concentration rarely approach toxic levels. 
 
Distribution 
The two-compartment model can describe this. The rapid 
distribution phase is believed to be related to uptake by rapid 
equilibrating tissue i.e., tissues that have high vascular perfusion. The 
slow distribution phase  is mainly a function of distribution to slowly 
equilibrating tissue, biotransformation and excretion of the 
compound. More highly perfused organs show higher concentrations 
of the drug. Bupivacaine is rapidly excreted by lung tissue. Though 
skeletal muscle does not show any particular affinity for bupivacaine 
it is the largest reservoir of the drug 
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PHARMACODYNAMICS 
Central Nervous System 
Bupivacaine readily crosses the blood brain barrier causing 
central nervous system depression following higher doses. The initial 
symptoms involve feeling of light-headedness and dizziness followed 
by visual and auditory disturbances. Disorientation and drowsiness 
may occur. Objective signs are usually excitatory in nature, which 
includes shivering, muscular twitches and tremors, initially involving 
muscles of the face (perioral numbness) and part of extremities. At 
still higher doses cardiovascular or respiratory arrest may occur. 
Acidosis increases the risk of CNS toxicity from bupivacaine, since 
an elevation of PaCO2 enhances cerebral blood flow, so that more 
anesthetic is delivered rapidly to the brain 
 
Autonomic nervous system 
Bupivacaine does not inhibit the Noradrenalin uptake and 
hence has no sympathetic potentiating effect. Myelinated 
preganglionic B fibers have a faster conduction time and are more 
sensitive to action of Bupivacaine. When used for conduction 
blockade, all local anesthetics, particularly bupivacaine produces 
higher incidence of sensory than motor fibers 
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Cardiovascular System  
The primary cardiac electrophysiological effect of a local anaesthetic 
is a decrease in the maximum rate of depolarization in Purkinje fibers 
and ventricular muscle. This action by bupivacaine is far greater 
compared to lignocaine and also, the rate of recovery of block is 
slower with bupivacaine. The resulting slowed conduction of the 
cardiac action potential manifest on the electrocardiogram as 
prolongation of the P-R and QRS intervals and reentry ventricular 
cardiac dysrhythmias. The R enantiomer of bupivacaine is more toxic 
than the S enantiomer. Bupivacaine reduces the cardiac contractility 
by blocking the calcium transport. Low concentration of bupivacaine 
produces vasoconstriction whereas high doses cause vasodilatation. 
 
Respiratory System 
Respiratory depression may be caused if excessive plasma 
level is reached which in turn results in depression of medullary 
receptor center. Respiratory depression may be also caused by 
paralysis of respiratory muscles of diaphragm as may occur in high 
spinal or total spinal anesthesia 
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Biotransformation and Excretion 
Bupivacaine undergoes enzymatic degradation primarily in the 
liver. The excretion occurs primarily via the kidney. Renal perfusion 
and factors affecting urinary pH affect urinary excretion. Less than 
5% of bupivacaine is excreted via the kidney unchanged through 
urine. The major portion of injected agent appears in urine in the 
form of 2,6 pipecolyoxylidine (ppx) which is a n-dealkylated 
metabolite of bupivacaine. Renal clearance of the drug is related 
inversely to its protein binding capacity and pH of urine. 
 
Adverse Effects 
Adverse effects are encountered in clinical practice mostly due 
to overdose, inadvertent intravascular injection or slow metabolic 
degradation. 
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Central nervous system 
It is characterized by excitation or depression. The first 
manifestation may be nervousness, dizziness, blurring of vision or 
tremors, followed by drowsiness, convulsions, unconsciousness and 
respiratory arrest. 
  
Cardiovascular system 
Myocardial depression, hypotension, arrhythmia, ventricular 
type conduction defect, SA node depression and cardiac arrest 
 
Allergic reactions  
Urticaria 
Bronchospasm 
Hypotension 
 Other - nausea, vomiting, chills, constriction of pupil and 
tinnitus 
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                        REVIEW OF LITERATURE 
 
      Prachee sachan et al41 in 2014 conducted a randomised 
contoled study  in  caesarean section  by administering intrathecal 
clonidine with hyperbaric bupivacaine as a mixture and sequential. 
They compared the block characteristics, intraoperative 
haemodynamics and postoperative pain relief. They randomly 
allocated  60 full-term parturients scheduled for elective caesarean 
sections were divided into two groups on the basis of technique of 
intrathecal drug administration. Group M received mixture of 
clonidine (75 mcg) and hyperbaric bupivacaine 0.5% (10 mg) 
intrathecally, whereas Group B received clonidine (75 mcg) 
followed by hyperbaric bupivacaine 0.5% (10 mg) through separate 
syringes. They observed duration of analgesia was significantly 
longer in Group B (474.33 ± 20.79 min) in which the drug was 
given sequentially than in Group M (337 ± 18.22 min). Furthermore, 
the time to achieve highest sensory block and complete motor block 
was significantly less in Group B without any major haemodynamic 
instability and adverse neonatal outcome. Therefore they concluded 
that when clonidine and hyperbaric bupivacaine were administered 
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in a sequential manner, block characteristics improved significantly 
compared to the administration of the mixture of the two drugs. 
Ranju singh et al40 in 2013 conducted a study to evaluate the 
effect of addition of intrathecal clonidine to hyperbaric bupivacaine 
on postoperative pain after lower segment caesarean section. : A total 
of 105 parturients carrying a singleton fetus at term, scheduled to 
undergo elective LSCS under spinal anaesthesia were randomized in 
a double  blind fashion to one of the three groups. Group BF (n=35) 
received 2ml of 0.5% hyperbaric bupivacaine+25 µg fentanyl, Group 
BC50 (n=35) received 2 ml of 0.5% hyperbaric bupivacaine+50 µg 
clonidine, Group BC75 (n=35) received 2 ml of 0.5% hyperbaric 
bupivacaine +75 µg clonidine. They observed that the duration of 
postoperative analgesia was 184.73±68.64 min in group BF, 
360.71±86.51 min in group BC50 and 760.50±284.03 min in group 
BC75,with P<0.001. Neonatal outcome was similar in all the three 
groups. They concluded  addition of 75 µg clonidine to hyperbaric 
bupivacaine in spinal anesthesia for LSCS significantly prolongs the 
duration of postoperative analgesia without any increase in maternal 
side effects. There was no difference in neonatal outcome. 
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Agreta Gecaj-Gashi, et al24 conducted a prospective, double-
blinded study in 2012 to evaluate the effects of clonidine in co-
administration with bupivacaine in spinal anesthesia, regarding the 
onset and regression of  sensory and motor block, postoperative 
analgesia and possible side effects. They  randomly selected 66 male 
patients (age 35 to 70),of ASA class I–II posted for transurethral 
surgical procedures.They  randomly allocated two groups of 33 
patients each, group B  received 0.5% isobaric bupivacaine 7.5 mg 
intrathecally and group BC  received bupivacaine 7.5 mg and 
clonidine 25 µg intrathecally.They observed  the mean time of 
achievement of motor block (Bromage 3) and sensory block at level 
T9 was significantly shorter in the group BC than with  group B (p = 
0.002, p = 0.000, respectively). The motor block regression time was 
not significantly different between the two groups (p = 0.237). The 
postoperative analgesia requirement was significantly longer in BC 
group than  with B group  (p = 0.000). No neurological deficit, 
sedation or other significant adverse effects were recorded. They 
concluded  intrathecal administration  of clonidine  with bupivacaine 
improves the duration and quality of spinal anaesthesia. It also 
provides longer duration of postoperative analgesia, without any 
significant side effects. 
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     S.desai et al27 in 2010 conducted a randomised controlled trial of 
hyperbaric bupivacaine  with opioids, injected as either a mixture or 
sequentially,  for spinal anaesthesia for caesarean section. Mixing 
these drugs may alter the density of the hyperbaric solution, affecting 
the spread of local  anaesthetic and opioid. Forty-eight women having 
elective caesarean section under spinal anaesthesia were recruited to 
this double-blind, randomised trial. Group M (n=24) received 2 ml of 
0.5% hyperbaric bupivacaine plus morphine 100 µg plus fentanyl 15 
µg, mixed in a syringe prior to administration. Group S (n=24) 
received  2 ml of 0.5% bupivacaine through one syringe, followed by 
morphine 100 µg plus fentanyl 15 µg through a  separate syringe. 
Block characteristics, postoperative pain scores and morphine use 
were noted. The patients in Group M had  higher levels of sensory 
block to  than those in Group S (median T2 versus T3)(P=0.003). 
There was no difference between groups in the incidence of 
hypotension, need for vasopressor or any other side-effects. 
Morphine consumption was significantly higher in group M 
(13.3±11.2 versus 6.2±7.2 mg, P=0.015). They concluded mixing of 
fentanyl and morphine with hyperbaric bupivacaine results in a 
higher level of sensory block than sequential administration of 
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bupivacaine then opioid and may be associated with higher 
postoperative opioid requirement. 
Imbelloni LE et al29 in 2009 conducted an experimental study 
to determine the density of local anaesthetic solutions, with and 
without glucose, and the combination of the local anesthetic with 
adjuvants at 20° C, 25° C, and 37° C. The density (g/mL) was 
determined by using a DMA 450 densimeter with a sensitivity of ± 
0.00001 g/mL . The densities, and variations, according to the 
temperature were obtained for all local anaesthetics and their 
combination with opioids at 20ºC, 25°C, and 37°C. The solution is 
hyperbaric if its density exceeds 1.00099, hypobaric when its density 
is lower than 1.00019, and isobaric when its density is greater than 
1.00019 and lower than 1.00099. The densities of both local 
anaesthetics and adjuvants decrease with the increase in temperature. 
At 37° C, all glucose- containing solutions are hyperbaric. In the 
absence of glucose, all solutions are hypobaric. At 37°C, morphine, 
fentanyl, sufentanil, and clonidine are hypobaric. They concluded the 
densities of local anaesthetics and adjuvants decrease with the 
increase in temperature and increase when glucose is added.  
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Patricia M. Lavand’homme et al26 conduted a study in 2008 
to evaluate the postoperative antihyperalgesic effect of intrathecal 
clonidine after caesarean delivery.  Ninety six parturients undergoing 
elective cesarean delivery were randomly allocated to Group BS 
(receive intrathecal bupivacaine-sufentanil) Group BSC 
(bupivacaine-sufentanil-clonidine 75 mcg) and GroupBC 
(bupivacaine-clonidine 150 mcg) . The primary outcome was the 
extent and the incidence of periincisional punctate mechanical 
hyperalgesia as assessed by response to application of a von Frey 
filament at 24 and 48 h after cesarean delivery.   They observed 
Group (BC ) had a significantly reduced area of periincisional 
hyperalgesia at 48 h ( 1.0 (1.0 – 3.3) cm2 versus Group BS 9.5 (5.0–
14.0) cm2 versus Group BSC 5.0 (2.5–12.3) cm2  (P = 0.02 with the 
BS group). The incidence of hyperalgesia at 48 h was also lower in 
the BC group: 16% versus 41% in the BS group versus 34% in the 
BSC group (P = 0.03 with BS group). Postoperative morphine 
consumption, pain scores did not differ among groups. They 
concluded Intrathecal clonidine 150 mcg combined with bupivacaine 
had a postoperative antihyperalgesic effect expressed as a significant 
reduction in  periincisional punctate mechanical hyperalgesia at 48 hr  
after elective cesarean section compared with intrathecal 
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bupivacaine-sufentanil and intrathecal clonidine 75 mcg-bupivacaine-
sufentanil. 
       B.S.Sethi et al33 conducted a study in 2007 to evaluate efficacy 
of analgesic effects of low dose intrathecal  clonidine as adjuvant to 
bupivacaine. Study conducted in  Sixty adult patients of  ASA grade I 
and II, posted for gynaecological surgery under spinal anaesthesia 
were randomly divided into two groups. Clonidine group received 
clonidine1µg/kg with12.5mg0.5% bupivacaine (The maximum dose 
of clonidine used was70µg) and the Control group received an 
identical volume of saline mixed with 12.5mg 0.5%bupivacaine. The 
mean time from injection to two segment regression  was longer in 
the clonidine group than in control group(P<0.001). The duration of 
motor blockade was longer in clonidine group (P<0.05) than control 
group. There was a significant difference (P<0.001) in the mean 
duration of analgesia between the two groups, the recordings 
being,614min (480–1140min) in the clonidine group as against 
223min (150- 300 min) in the control group.The rescue analgesia was 
required earlier in the Control group (mean223min) than clonidine 
group (mean614min).The patients in the clonidine group had a 
significant fall in heart rate and mean arterial pressure and were more 
sedated than those in control group, however, no therapeutic 
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interventions needed. They concluded that addition of clonidine to 
bupivacaine in the dose of 1µg/kg significantly increases the duration 
of spinal analgesia as compared to bupivacaine alone with clinically 
insignificant influence on haemodynamic parameters and level of 
sedation.  
          Van tuijl et al30 in2006 conducted a randomized control trial 
to investigate the effect of the addition of clonidine (75 mg) to 
hyperbaric bupivacaine on postoperative morphine consumption after 
Caesarean section. A group of 106 women received spinal 
anaesthesia using either bupivacaine 0.5% (2.2 ml) heavy with 0.5 ml 
normal saline 0.9% (B) or bupivacaine 0.5% (2.2 ml) heavy with 
clonidine (75 mcg) in 0.5 ml normal saline 0.9% (BC).They observed 
the mean time to the first analgesic request in the BC group was 129 
(SD 13.8) min, compared with 55 (14.2) min in the B group. They 
concluded the addition of clonidine (75 mcg) to hyperbaric 
bupivacaine prolongs duration of spinal anaesthesia after Caesarean 
section and improves early analgesia, but does not reduce 
postoperative morphine consumption during the first 24 hour.   
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Neves JF et al39 conducted a study in 2006 to evaluate  the 
addition of 15 to 30 µg of clonidine to 0.5% hyperbaric bupivacaine 
(12.5 mg) with  morphine(100 µg) in spinal anesthesia for caesarean 
sections to  improve the quality of postoperative analgesia,they 
randomly allocated sixty patients into three groups.Group BM 
received 0.5% hyperbaric bupivacaine 12.5mg and morphine 100mcg 
,Group BM15 – 0.5% hyperbaric bupivacaine (12.5 mg), morphine 
(100 µg), and clonidine (15 µg), and Group BM30 – 0.5% hyperbaric 
bupivacaine (12.5 mg), morphine (100 µg),and clonidine (30 µg), 
administered separately. Intra operatively the use of ephedrine and 
the newborn’s Apgar score were recorded. In the postoperative 
period, the pain was evaluated in the 12th hr by the VAS score. They 
observed the use of ephedrine and the evaluation by the Apgar score 
did not show statistically significant differences among the different 
groups. The duration of post operative analgesia was increased in 
those received clonidine. So they concluded that the addition of 
clonidine to 0.5% hyperbaric bupivacaine (12.5 mg) with morphine 
(100 µg)in spinal anaesthesia  for caesarean section improved the 
quality of postoperative analgesia without increasing the incidence of 
side effects. 
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Kaabachi O et al32 conducted a    prospective randomised 
study in 2002 to evaluate the effect of intrathecal clonidine in 
children .  45 children, 6 to 15 years old, were randomised in two 
groups; receiving either 0.5% hyperbaric bupivacaine or 0.5% 
hyperbaric bupivacaine added to clonidine 2 µg·kg–1. They assessed 
quality and duration of motor and sensory blocks and side effects of 
clonidine such as hypotension, bradycardia  and sedation were noted. 
They obseved Clonidine was associated with prolongation of motor 
block, 190 ± 42 min vs 150 ± 35 min (p < 0.01), but the difference 
was not significant. Postoperative analgesia was longer in clonidine 
group, 490 ± 35 min vs 200 ± 50 min (mean ± SD), p < 0.001. 
Clonidine was associated with higher incidence of hypotension and 
bradycardia .They concluded  that intrathecal clonidine 2 µg·kg–1 is 
associated with longer duration of postoperative analgesia but with 
moderate side effects such as hypotension, bradycardia. 
Fonseca NM et al42 in 2001 conducted a study to evaluate the 
effects of combined clonidine and 0.5% hyperbaric bupivacaine on 
spinal anaesthesia. Thirty ASA I or II patients of both genders, aged 
between 16 and 57 years and scheduled to undergo  inguinal hernia 
repair were randomly allocated into three groups. Group I received 
bupivacaine 15 mg plus150 µg clonidine, Group II received 
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bupivacaine 15 mg and 75 µg clonidine + 0.5 ml distilled water and 
Group III received bupivacaine 15 mg plus 1 ml of distilled water. 
The following parameters were evaluated: sensory block level at 5, 
20 and 30 minutes, time for two segment regression, sedation scores , 
motor block by a modified Bromage scale, postoperative pain and 
analgesics requirement. They observed maximum sensory level  were 
similar for all groups. Duration of sensory and motor block were 
longer for Group I. There were no difference in sedation and 
hemodynamic parameters between groups. Group I had a prolonged 
analgesia as compared to other groups. They concluded that clonidine 
has not changed cephalad spread and hemodynamic effects of spinal 
anaesthesia with hyperbaric bupivacaine. It was however effective in 
improving analgesia observed until the fourth hour after the blockade, 
as well as in prolonging anaesthesia duration, being therefore useful 
as a co  adjuvant of spinal blocks with hyperbaric bupivacaine. 
        Dan Benhamou et al22 conducted a multi center trial in1998 in 
Seventy eight pregnant women at term, scheduled for elective 
caesarean section, to compare the analgesic efficacy and side effect 
profile of hyperbaric bupivacaine alone (Group B) or bupivacaine 
combined with  clonidine (Group BC) or with clonidine  and 
fentany1 (Group BCF).  Group B received hyperbaric bupivacaine 
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and 1 ml of saline, Group BC received hyperbaric bupivacaine with 
clonidine 75 µg (0.5 ml) and saline (0.5 ml), and in Group BCF 
received bupivacaine with fentanyl (12.5 µg in 0.5 ml) added to 
clonidine (75 µg). The dose of bupivacaine was similar in all groups 
(0.06 mg/cm of body height). They observed clonidine increased the 
spread of the sensory block and decreased pain and analgesic 
supplementation intra operatively. This improved analgesia was best 
with the clonidine fentanyl combination (Group BC versus Group 
BCF; P < 0.05). Postoperative analgesia was prolonged only in Group 
BCF (215 ± 79 min versus 137 + 35 and 183 ± 80 min for Group 
BCF versus Groups B and BC; P < 0.05).   Blood pressure and heart 
rate changes were not significantly different among groups, except 
sedation and pruritis which were significant in Group BCF.  Apgar 
scores and umbilical artery blood pH were not different among 
groups. They concluded  adding a small dose of intrathecal clonidine 
(75mcg) to bupivacaine increases the quality of intra operative 
analgesia without adverse neonatal outcome. The combination of 
clonidine and fentanyl further improved analgesia with moderately 
increased sedation and pruritis. 
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Heo GJ et al35 conducted a study in 1997 to evaluate effect of 
intrathecal clonidine in hyperbaric bupivacaine spinal 
anesthesia.  They randomly allocated thirty patients who were 
scheduled for lower limb or urologic operation and were divided  into 
2 groups: Group A (hyperbaric bupivacaine 13 mg, 2.6 ml + 
0.9%saline 1 ml), Group B (hyperbaric bupivacaine 13 mg, 2.6 ml + 
clonidine 150mcg, 1 ml). They used standardized techniques and 
injected above drugs to group A and B intrathecally for spinal 
anesthesia. They observed the onset and the duration of spinal 
anaesthesia along with hemodynamic changes (blood pressure and 
heart rate).  They observed   no significant differences in the onset of 
spinal anaesthesia and hemodynamic changes between two groups. 
The time taken to recover from the nerve block was more prolonged 
in the group B (touch 225, pain 262, foot dorsiflexion 271, knee 
flexion 290 minutes) than group A (touch 154, pain 188, foot 
dorsiflexion 198, knee flexion 216 minutes).  No significant 
differences in sedation, dry mouth and other side effects between the 
two groups. They concluded that Intrathecal clonidine 150mcg  
prolong the duration of hyperbaric 0.5% bupivacaine spinal 
anesthesia without neurotoxicity or dangerous hemodynamic 
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instability. Therefore, clonidine can be used as an effective adjuvant 
to hyperbaric bupivacaine in spinal anaesthesia. 
Michael G Richardson et al43 in 1996 conducted a study to 
determine the exact density of human cerebrospinal fluid and 
determine  whether CSF density altered by pregnancy.density 
measurements accurate to 0.00001 g/ml were made at 37℃, using a 
mechanical oscillation resonance frequency density meter. CSF 
samples were obtained from 44 patients during spinal anaesthesia. 
Five groups were studied : men and premenopausal, postmenopausal, 
term pregnant and postpartum women.  They observed mean CSF 
densities in men (1.00064±0.00012 g/ml), postmenopausal women 
(1.00070±0.00018 g/ml) and non pregnant premenopausal 
(1.00049±0.00004 g/ml) were significantly greater than in term 
pregnant (1.00030±0.00004 g/ml) and postpartum (1.0004±0.00005 
g/ml) women. Cerebrospinal fluid density did not correlate with age.
 Therefore they concluded mean CSF density varies in different 
patient subpopulations.  Pregnancy and the immediate postpartum 
period are associated with the lowest CSF densities.  In addition, the 
cutoff values defining hypobaricity(mean CSF desnity minus three 
standard deviations) are greater than previously reported.  Accurate 
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CSF density values should be used when considering baricity as a 
mechanism for clinical observations of dextrose –free intrathecal 
local anesthetics and opioids. Gestational status also should be 
considered.  
Gray et al36 in 1986 investigated possible differences in the 
duration of postoperative analgesia and the incidence of respiratory 
depression after the intrathecal injection in the lumbar area of 10 
mcg/kg morphine in hypobaric and hyperbaric solution for relief of 
post thoracotomy pain. Twenty-nine patients received morphine plus 
dextrose (hyperbaric) and 21 received morphine in preservative-free 
normal saline. They observed the duration of analgesia was longer 
with the morphine in the normal saline group than in the hyperbaric 
group (P < 0.04). They concluded morphine in normal saline 
mixtures produce greater duration of analgesia than morphine plus 
dextrose. 
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                           MATERIALS AND METHODS 
After getting approval from the institutional ethical 
committee,the study was conducted in sixty parturients undergoing 
elective caesarean section under spinal anaesthesia. The patients were 
randomly allocated into two groups of 30 each by sealed envelope 
technique. 
Inclusion criteria 
• ASA grade1&2 
• Single live fetus 
• Uncomplicated pregnancy 
Exclusion criteria 
• Patient refusal 
• Contraindication to subarachnoid block 
• Multiple pregnancy 
• Intrauterine death 
• Known fetal anomaly 
• Severe pregnancy induced hypertension 
• Patient on cardiovascular medications 
• Hypersensitivity to clonidine and local 
anaesthetis 
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All patients were thoroughly examined preoperatively. 
informed written consent obtained and the procedure was explained. 
they were allocated into following groups. 
 
Group M: 10mg of 0.5%hyperbaric bupivacaine plus 
clonidine75microgram as a mixture in single syringe. 
 
Group   B: clonidine 75 microgram followed by hyperbaric 
bupivacaine 10mg in different syringes. 
 
For our study, the drugs used were sourced from same 
company to avoid manufacturer’s difference. hyperbaric bupivacaine 
used was HEAVY ANAWIN and clonidine used was CLONEON 
manufactured by neon laboratories. 
 
Patients were kept fasting overnight and oral ranitidine 150 mg 
at night and on the morning prior to surgery were given. The patients 
were familiarised with concept of visual analogue scale (VAS) for 
pain assessment with o=no pain and 10= worst pain. 
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In the operating room, monitor for heart rate (HR),non invasive 
blood pressure, electrocardiography and oxygen saturation (SpO2) 
was connected and baseline parameters were recorded. after 
establishing 18 gauge venous cannula, patients were preloaded with 
15 ml/kg of lactated ringer solution 15-20 min before spinal block. 
Under all aseptic precautions subarachnoid block was administered 
with 23 G Quincke spinal needle through midline approach in sitting 
position. Intrathecal drug was injected in L3-L4 inter space over 30 
seconds (including the time for change of syringe in sequential 
administration). After the block was performed, the patients were 
made supine with 15-20 degree left displacement of uterus until 
delivery of baby by keeping wedge. Fluid therapy was maintained 
with ringer lactate 10 ml/kg/hr. 
 
HAEMODYNAMIC PARAMETERS 
Heart rate, systolic arterial pressure (SAP), diastolic pressure 
(DAP) were monitored  every 2 minutes for the first 20 minutes and 
then every 5 minute subsequently until 75 minutes or until 
completion of surgery. 
 
 
72 
 
Hypotension (decrease in systolic pressure below 90 mmHg or 
fall in blood pressure >20% of baseline values) was treated with a 
rapid infusion of crystalloids 200 ml and a bolus of injection 
ephedrine 5mg intravenous was administered if hypotension 
persisted. Bradycardia heart rate <50 beats/minute was treated with 
injection atropine 10mcg/kg intravenously. 
 
SENSORY AND MOTOR BLOCK 
 
Sensory block was assessed by loss of pinprick sensation to 
23G  hypodermic needle in the midclavicular line bilaterally.  
Onset of sensory blockade: is defined as time taken from the  
completion of the injection of study drug till the patient does not feel  
the pin prick at T10 level.  
Time taken for maximum sensory blockade: is defined as the time  
taken from the completion of the injection of the study drug to the  
maximum sensory blockade attained. Sensory level was tested every  
2 minutes until the highest sensory level (maximum block height) had  
stabilized for four consecutive tests.  
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Furthermore level was tested every 30 minutes until regression from  
highest level to T10 dermatome was noted. 
 
MOTOR BLOCK 
Onset of motor block: is defined as the time taken from the 
completion of injection of study drug till patient develops Bromage 
score2. 
Time to achieve complete motor block: is defined as the time 
taken from the completion of injection of study drug till patient 
unable to move legs and feet. 
          Duration of motor blockade: is defined as the time taken 
from the time of injection till the patient attains complete motor 
recovery. 
Degree of motor block was assessed by Bromage scale as 
follows 
1 : Free movement of legs and feet 
2 : Just able to flex knees with free movement of feet 
3 : Unable to flex knees with free movement of feet 
4 : Unable to move legs and feet 
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                   Motor block was assessed at the same interval as sensory 
block. Onset of motor block was assessed by time to reach bromage 
score2. Time to achieve complete motor block (bromage4) and its 
regression to  bromage 1 was noted. 
 
RESPIRATION 
 
Respiratory depression was defined as rate <10breath/minute 
or Spo2 <92%. Oxygen was then supplemented through O2 mask 
4L/minute. 
                                                                                                    
SEDATION 
             Sedation score assessed same interval as sensory block until 
2 hr postoperatively by Ramsay sedation score (RSS) as: 
Level 1 - awake, anxious, agitated, restlessness 
Level 2 – awake, tranquil, co-operative 
Level 3 – responds to commands 
Level 4 – asleep, brisk response to stimuli 
Level 5 – asleep, sluggish response to stimuli 
Level 6 – asleep, no response to stimuli 
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ANALGESIA 
Duration of analgesia: is defined as the time taken from the  
completion of the injection of the study drug till the patient requests  
for rescue analgesic in the post operative period 
     Intra operative and post operative pain was checked and expressed 
as VAS, whenever the parturients complained of discomfort or pain. 
Duration of analgesia was defined as time of intrathecal 
administration to VAS >3. If VAS >3 then rescue analgesia in the 
form of intravenous diclofenac sodium 75 mg was given. 
 
VISUAL ANALOGUE SCALE 
 
Patients complaining of nausea or vomiting were given 
injection ondansetron 0.15mg/kg IV. Any complaint of dry mouth 
was noted. Newborns APGAR scores were determined by a 
paediatrician not otherwise involved in the study  at 1, 5, and 10th 
minute. 
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Post-operatively any incidence of bradycardia, hypotension, 
nausea, vomiting was noted and treated accordingly. They were asked 
about the presence of headache (PDPH), back pain, numbness and 
tingling sensation in the lower extremities. 
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                         STATISTICAL ANALYSIS: 
 
      The information collected regarding all the selected cases were 
recorded in a master chart. Data entry was done using SPSS 21 for 
Windows. Descriptive statistics like percentages, mean with standard 
deviation and 95% confidence interval were used.  
Independent t test was used to find the significance of 
difference between the two means and a P value of less than 0.05 was 
considered statistically significant 
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OBSERVATION AND RESULTS 
 
              All 60 patients in two groups completed the study without 
any exclusion. We did inter group analysis and the results were as 
followed. Of the 60 patients 30 belongs to Group M [mixture of 
clonidine75mcg and  hyperbaric  bupivacaine 0.5%(10 mg)] and 
other 30 categorized  as Group B [clonidine 75 mcg followed by 
hyperbaric bupivacaine 0.5%(10 mg)]. Data were presented as 
maximum, minimum, mean, standard deviation. The probability 
value ‘ p’ of less than 0.05 was considered as statistically significant. 
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The above table shows the demographic data in terms of age, height, 
weight and duration of surgery and they are comparable in both 
groups. They are found to be statistically insignificant. 
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The above figure shows the age distribution of the patients and more 
than half of the patients, 31(51.6%) of the patients belong to the age 
group of 20-25 years. 
 
 
 
 
Fig 1: Age distribution of the patients (n=60) 
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Table 2 shows the mean duration of surgery between the Group M 
and Group B, and it is found to be 79.33±6.98 min and 80.30±1.84 
min respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Duration of surgery 
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Table 3 shows the onset of sensory block between the Group 
M and Group B, and it is found to be 65.03±10.38 and 61.93±2.21 
respectively. It is statistically insignificant .(p value 0.115). 
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This graph shows the onset of sensory block between the GroupM  
 
and Group B 
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Table 4 shows the time to reach the maximum height of 
sensory block and it is found to be maximum of 7 minutes and 
minimum of 2 minutes in group M with a mean of 4.57 minutes and 
among group B, it is found to have a maximum of 5 minutes and a 
minimum of 2 minutes, with a mean of 3.50 minutes.  Mean time to 
reach maximal cephalad-sensory block height was significantly less 
in Group B (3.50±0.97 min) than in Group M (4.57±1.94 min) with 
  p value of 0.000. 
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This graph shows the time to reach the maximum height  of sensory  
 
block between the Group M and Group B 
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The above table shows the regression time between the group 
M and group B and it is found to have an average of 162.03 minutes 
in group M and 238.67 minutes in group B with SD of 11.62 and 
27.90 minutes respectively. Significant prolongation of sensory block 
in group B ( p value 0.000). 
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This graph shows the regression time to T10 between the Group M  
 
and Group B 
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The above table shows the total duration of analgesia between 
the group M and group B and it is found to have an average of 322.53 
minutes in group M and 432.60 minutes in group B with SD of 23.24 
and 64.65 minutes respectively. The total duration of analgesia lasted 
significantly longer in Group B (432.60±64.65 min) as compared to 
Group M (322.53±23.24 min) (P=0.000) 
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This graph shows the total duration of analgesia between the Group  
 
M and Group B 
 
 
 
 
90 
 
 
Table 7 shows the onset of motor block and it is found to be 
maximum of 4 minutes and minimum of 1 minute in group M with a 
mean of 2.80 minutes and among group B, it is found to have a 
maximum of 4 minutes and a minimum of 1 minute, with a mean of 
2.47 minutes. Onset of motor block was comparable in both groups 
and is found to be statistically insignificant with p value 0.171. 
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This graph shows the time of onset of motor block between the  
 
Group M and  Group B 
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The above table shows the time to achieve complete motor 
block between the group M and group B and it is found to have an 
average of 5.57 minutes in group M and 5.03 minutes in group B 
with SD of 1.10 and 0.92 minutes respectively. Complete motor 
blockade was achieved earlier in Group B (5.03±0.92 min) than in 
Group M (5.57±1.10 min) (P=0.047). It is found to be statistically 
significant. 
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This graph shows the time to complete motor block between the  
 
Group M and  Group B 
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The above table shows the resolution time of motor block 
between the group M and group B and it is found to have an average 
of 199.77 minutes in group M and 286.03 minutes in group B with 
SD of 38.23 and 16.90minutes respectively. ). The resolution time of 
motor block was significantly prolonged in Group B (286.03±16.90 
min) than in Group M (199.77±38.23 min), P=0.000.It is statistically 
significant. 
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This graph shows the resolution time  of motor block between the  
 
Group M and  Group B 
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Table 10: Characteristics of sensory and motor block 
Variables  
Group  
P value  
Group M  Group B  
Onset of sensory block (sec)  65.03±10.38  61.93±0.404  0.115  
Maximum sensory block 
height(T) ,median  
T4(T3-T5)  T4(T3-T5)  NS  
Time to reach maximum 
cephalad sensory block height 
(min)  
4.57±1.94  3.50±0.97  0.000  
Regression time to T10 (min)  162.03±11.62  238.67±27.90  0.000  
Total duration of analgesia (min)  322.53±23.24  432.60±64.65  0.000  
Onset time of motor block (min)  2.80±1.06  2.47±0.77  0.171  
Time to complete motor block 
(min)  
5.57±1.10  5.03±0.92  0.047  
Resolution time of motor block 
(min)  
199.77±38.23  286.03±16.90  0.000  
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The onset time of sensory and motor block and also the highest 
level of block achieved (T5) are comparable in both groups [Table 
10]. Mean time to reach maximal cephalad-sensory block height was 
significantly less in Group B (3.50±0.97 min) than in Group M 
(4.57±1.94 min) with p value of 0.000 and the total duration of 
analgesia lasted significantly longer in Group B (432.60±64.65 min) 
as compared to Group M (322.53±23.24 min)(P=0.000). Complete 
motor blockade was achieved earlier in Group B (5.03±0.92 min) 
than in GroupM(5.57±1.10 min)(P=0.047).  
 
The resolution time of motor block  was significantly 
prolonged in Group B (286.03±16.90 min) than in Group M 
(199.77±38.23 min), P=0.000. 
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Fig 2: Heart rate at different time intervals 
 
Hemodynamic parameters showed that the lowest values of the 
HR are after 45 min of the administration of SAB, but none of the 
patients had bradycardia. 
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There is a significant fall in SAP at 2 min and 4 min after 
administration of SAB in both groups. 
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A significant fall in DAP was seen at 2, 4, 6, and 8 min of 
administration of SAB. There was an overall trend of fall in SAP and 
DAP in both groups, except during the time intervals of20 and 25 
min (during delivery of baby) where there was rise in both SAP and 
DAP. The falling trend of arterial blood pressures was more in the 
Group B than in Group M  it is found to be statistically insignificant. 
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The figure above shows the incidence of complications between the 
groups M and B and is found to be comparable in both the groups. It 
is found that hypotension was present in 8(26.7%) and 10(33.3%) of 
the patients in group M and group B respectively and vasopressor 
was used in 1 patient among group M and 3 patients in group B. 
Vomiting was present in 5(16.7%) and 9(30.0%) of the patients 
respectively. 
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DISCUSSION 
We conducted randomized control study to evaluate the 
efficacy of premixed versus sequential administration of clonidine as 
an adjuvant to hyperbaric bupivacaine intrathecally in caesarean 
section. Background of the study was mixing adjuvants with 
hyperbaric bupivacaine in a single syringe before injecting the drugs 
intrathecally is an age old practice. In doing so, the density of the 
hyperbaric solution and also of the adjuvant drugs may be altered, 
thus affecting the spread of drugs. Administering local anaesthetic 
and the adjuvants separately may minimise the effect of the changes 
in densities 
The observation and results obtained in the study are based on 
the assumption that the original densities of hyperbaric bupivacaine 
and clonidine are lost when they are premixed in a syringe thus 
exerting sub optimal actions when compared to sequential manner of 
administering the drug . Our assumption is supported by the work of 
prachee sachan et al who conducted a randomised contol study  in  
caesarean section  by administering intrathecal clonidine with 
hyperbaric bupivacaine as a mixture and sequential, and  desai et 
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al.,27 Who studied the same effect by adding opioids to local 
anaesthetic solution intrathecally in caesarean section. 
Various authors have used different doses of intrathecal clonidine 
ranging from 15 mcg to 300 mcg along with local anaesthetics. 
kaabachi et al.,32 in their study used 2 mcg /kg of intrathecal 
clonidine and reported extended duration of post operative analgesia, 
but with moderate side effects. sethi et al., 33 used 70 mcg of 
clonidine and found a significant decrease in mean arterial pressure 
and heart rate in clonidine group, but no therapeutic intervention was 
required for either. 
A recent study by ranju singh et al., 40 on intrthecal clonidine with 
hyperbaric bupivacaine in caesarean section showed that a dose of 75 
mcg clonidine increased the duration of analgesia significantly 
without increasing maternal side effects. 
 Similarly van tuijl et al., 30 demonstrated that addition of 75 mcg of 
clonidine to hyperbaric bupivacaine  prolongs spinal analgesia  and 
the motor block in caesarean sections without maternal or neonatal 
side effects. Therefore we used 75 mcg of clonidine and found that it 
helps achieving a faster block and longer duration of action without 
worrisome hemodynamic variability or side effects. 
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The densities of the drugs that we used separately (hyperbaric 
bupivacaine and clonidine) were 1.0260 and 0.9930, respectively. 
The density of the mixture of 2 ml (10 mg) of hyperbaric bupivacaine 
and 0.5 ml (75 mcg) clonidine was also estimated and it was found to 
be 1.0189. 
In our study, we observed that the mean onset time of sensory and 
motor block was similar in both groups. However, the onset of 
sensory block does not get any better after a particular dose as 
supported by a study done by heo et al., 35 who did not report any 
difference in onset time of sensory or motor block even after using 
150 mcg clonidine. 
The time to reach maximum sensory block height and a complete 
motor block was significantly less in Group B (sequential drugs) than 
in Group M (mixed drugs) in our study. This difference might have 
existed because of the preferential cephalad spread of clonidine when 
we administered it through a separate syringe, owing to its hypobaric 
nature which was lost when the drugs were premixed. 
In our study, we found that the mean time taken for sensory block to 
regress to T10 level was significantly longer in Group B (238.67 ± 
27.90 min) than in Group M (162.03 ± 11.62 min) and mean time 
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taken for motor block regression also significantly longer in Group B 
(286.03±16.90) than in Group M (199.77±38.23). Similarly, the mean 
duration of analgesia lasted significantly longer in Group B (432.60 ± 
64.65 min) than in Group M (322.53 ± 23.24 min), depicting 
significant prolongation of analgesic effect in the group receiving 
drugs in a sequential fashion. This difference might be due to the fact 
that injecting clonidine and bupivacaine as a mixture dilutes clonidine 
and receptor occupancy might decrease leading to less pronounced 
effect. However, if clonidine is administered separately, we expect a 
greater spread and therefore formation of stronger bonds with the 
receptor leading to a denser and prolonged block. 
According to desai et al., 27 dextrose in a hyperbaric solution slow the 
movement of morphine molecules in the CSF, reducing the exposure 
of supraspinal centres to morphine. Clonidine also being hypobaric 
drug, acting on both spinal and supraspinal receptors, might exhibit 
similar properties. Gray et al., 36 observed that duration of analgesia 
is increased when intrathecal morphine is administered with normal 
saline (hypobaric) than with dextrose saline (hyperbaric). 
Activation of post-synaptic alpha-2 receptors in the substantia 
gelatinosa of the spinal cord is the presumed mechanism by which 
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clonidine produces analgesia. These receptors are located on primary 
afferent terminals (both at peripheral and spinal endings), on neurons 
in the superficial lamina of the spinal cord, and within several 
brainstem nuclei implicated in analgesia, supporting the possibility of 
analgesic action at peripheral, spinal, and brainstem sites. 
Clonidine decreases heart rate by a presynaptic mediated inhibition of 
nor epinephrine release and by a direct depression of atrioventricular 
nodal conduction after systemic absorption. The maximum fall in the 
heart rate when compared to the baseline was 19% in Group B, 
whereas it was only 12% in Group M which was statistically 
significant (P < 0.001). This fall in heart rate was more pronounced 
after about 40-60 min of administration of subarachnoid block and 
toward end of the surgery. However, in our study none of the patients 
had bradycardia. 
A significant fall in arterial blood pressure after subarachnoid block 
was observed in our study. The fall from baseline SAP and DAP in 
Group M was 10% and 14% and in Group B was 8% and 13%, 
respectively. Haemodynamic effects of clonidine after neuraxial or 
systemic administration begin within 30 min, reach maximum within 
1-2 h, and last approximately 6-8 h after a single injection. We 
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observed hypotension in 26.7% of patients in group M and 33.3% of 
patient in group B. Hypotension was managed by i.v fluids and 
vasopressors were needed for only 1% and 3% parturients in Groups 
M and B, respectively which was comparable in both groups, 
suggesting that the clonidine groups did not have a higher 
predisposition for the development of significant hypotension if 
administered sequentially than mixed groups. In our study, the level 
of sedation provided by intrathecal clonidine (RSS 2 and 3) was not 
only acceptable, but also beneficial owing to its anxiolytic role. 
None of the patients needed any additional analgesics during the 
intra-operative period. In line with our observations, Benhamou et 
al. 22 found that when intrathecal clonidine was administered with 
hyperbaric bupivacaine, none of patients required additional 
analgesics to obtain an adequate sensory block. None of the patients 
complained of dry mouth. 
 There was no incidence of hypotension, bradycardia and 
nausea/vomiting, neurological deficit, prolonged sedation in the post-
operative period. 
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The APGAR scores in our study were statistically comparable in both 
groups. Benhamou et al. 22 and Neves et al. 39 also concluded that 
addition of intrathecal clonidine did not adversely affect the neonatal 
outcome in terms of APGAR scores. 
         In our study we, measured the densities of solutions in vitro but, 
we could not measure the densities when injected into the CSF. 
Hence, we could not assess what actually happens to the drug 
densities intrathecally. Similarly, effects of temperature of drugs 
when injected were not considered. 
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SUMMARY 
       
Sixty parturients of ASA 1&2  undergoing elective caesarean 
section under spinal anaesthesia were enrolled in this randomised 
controlled study.  They were equally and randomly allocated into two 
groups of 30 each namely Group M and Group B. 
 
     Patients in Group M received 10mg of 0.5%hyperbaric 
bupivacaine with  clonidine 75 microgram as a mixture in single 
syringe. Patients  in Group  B received clonidine 75 microgram 
followed by hyperbaric bupivacaine 10mg in different syringes. 
 
They were observed for onset and duration of sensory and 
motor block, total duration of analgesia ,hemodynamic changes, 
neonatal outcome, sedation and adverse effects. The collected data 
was analysed using independent t test and a p value <o.o5 was 
significant. 
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  Sequential administration of clonidine reduces the time to 
achieve complete motor and maximum sensory block and 
significantly prolongs total duration of analgesia without any 
significant adverse effect like sedation, hypotension or bradycardia or 
dryness as compared to the administration as a  mixture of 
bupivacaine and clonidine. 
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                                   CONCLUSION  
        Sequential administration of clonidine reduces the time to 
achieve complete motor and maximum sensory block and 
significantly prolongs total duration of analgesia when compared to 
mixture of hyperbaric bupivacaine and clonidine. Addition of 
clonidine to hyperbaric bupivacaine provide dense surgical 
anaesthesia  without any significant maternal and neonatal adverse 
outcomes, and without any significant unwanted side effects.  
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Fig.1 : VERTEBRAL COLUMN 
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FIG2  LATERAL VIEW OF LUMBAR VERTEBRAL 
COLUMN 
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Cross and longitudinal section 
 
 
FIG 6.: VERTEBRAL LIGAMENTS 
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FIG –7: BLOOD SUPPLY OF THE SPINAL CORD 
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PROFORMA 
Name:   Age/Sex:    IP No: 
ASA Physical status:       Date:  
Pre Operative: 
General examinations: 
PR :    CVS : 
BP :    RS : 
RR :    SPO2 : 
Diagnosis : 
Proposed surgery : 
Premedication : Tab. Ranitidine 150mg Night & Morning prior to   
surgery 
Group B/Group M 
Time of subarachnoid injection   :  
Onset time of sensory block(secs)  : 
Height of maximum sensory block  : 
Time to reach maximum sensory block(mts) : 
Regression time to T10(mts)   : 
123 
Total duration of analgesia (mts)  : 
Onset Time of motor block (mts)  : 
Time to complete motor block (mts)  : 
Resolution time of motor block(mts)  : 
Intra operative hemodynamics 
Mts 0 2 4 6 8 10 12 14 16 18 20 25 30 35 40 45 50 55 60 65 70 75
HR
SBP
DBP
  
Sedation score( until 2hr Post operatively) 
Level 1 : Awake, anxious Level 4 : Brisk response to stimuli 
Level 2 : Awake, tranquil Level 5 : Suggish response to stimuli 
Level 3 Responds to commands Level 6 : No response 
Post operative VAS score: 
 
Side effects 
 Badycardia     Hypotension 
 Nausea & Vomiting   Sedation 
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1 M 25 60 156 55 90 T6 7 150 310 2 8 180 125 67 70 98 yes no no yes no no no 
2 B 28 65 160 78 60 T4 2 258 337 3 6 267 118 68 91 98 yes no no no no no no 
3 M 23 58 155 78 40 T6 4 153 300 1 4 200 126 80 106 99 no no no no no no no 
4 B 29 64 156 82 65 T4 3 222 450 2 5 278 125 81 90 99 no no no no no no no 
5 B 24 56 160 80 60 T6 5 250 466 4 6 260 110 70 94 98 yes yes no yes no no no 
6 M 24 57 148 78 70 T6 5 150 360 3 7 300 129 81 116 99 no no no no no no no 
7 M 21 56 150 84 60 T5 5 150 310 2 5 200 116 70 97 98 no no no no no no no 
8 B 21 57 152 80 60 T4 2 244 355 2 3 322 110 80 88 99 yes yes no no no no no 
9 M 31 62 156 79 60 T5 4 155 350 3 5 272 125 81 107 98 no no no no no no no 
10 M 25 65 165 84 64 T6 4 170 360 2 4 280 120 78 91 97 no no no no no no no 
11 B 26 61 154 80 65 T4 3 262 322 3 5 298 120 70 82 99 yes yes no yes no no no 
12 M 30 62 155 80 62 T4 4 153 337 2 6 190 110 70 78 99 yes no no no no no no 
13 B 25 60 157 81 60 T4 3 240 470 2 4 290 126 78 86 98 no no no no no no no 
14 B 27 58 159 78 65 T6 4 256 450 2 4 300 130 78 89 99 no no no no no no no 
15 M 25 61 155 82 70 T6 3 170 350 2 4 190 126 72 98 99 no no no no no no no 
16 M 30 62 162 82 72 T4 3 180 322 3 6 178 124 76 99 99 yes no no no no no no 
17 B 27 58 156 80 62 T4 3 250 480 2 6 300 120 80 76 98 yes no no no no no no 
18 M 24 56 156 80 68 T5 5 166 300 4 6 176 132 86 78 99 no no no no no no no 
19 B 29 61 165 79 60 T6 4 250 500 3 5 287 128 82 86 99 no no no no no no no 
20 M 24 56 156 80 68 T5 6 178 300 4 6 176 132 86 78 99 yes yes no yes no no no 
21 B 22 58 152 79 60 T4 3 163 315 2 4 312 118 74 84 99 no no no yes no no no 
22 B 27 64 166 81 62 T6 2 164 317 2 3 266 128 68 92 98 no no no no no no no 
23 M 26 62 156 80 74 T4 4 176 290 4 5 168 128 72 78 99 no no no no no no no 
24 B 28 60 157 81 65 T4 3 233 470 2 4 290 126 78 84 98 no no no no no no no 
25 B 24 56 160 80 60 T6 5 250 466 4 5 260 120 70 94 98 yes yes no yes no no no 
26 B 22 57 258 85 60 T4 3 240 490 1 4 278 124 76 78 99 yes yes no no no no no 
27 M 26 58 160 82 68 T5 6 166 300 3 5 170 122 76 82 99 no no no yes no no no 
28 B 23 59 157 86 60 T4 3 255 444 2 5 300 126 88 86 98 yes yes no yes no no no 
29 B 25 60 157 81 60 T4 3 240 470 2 5 290 126 78 86 98 no no no no no no no 
30 B 25 60 157 81 60 T4 3 240 470 2 5 290 126 78 86 98 no no no no no no no 
31 M 31 56 156 80 68 T5 5 166 300 4 6 176 132 86 78 99 no no no no no no no 
32 M 32 62 167 84 72 T4 5 188 342 3 6 180 128 80 86 99 no no no no no no no 
33 M 24 56 156 80 68 T6 5 160 312 4 6 190 110 78 78 99 yes no no no no no no 
34 B 29 58 156 80 62 T6 5 240 480 2 6 300 120 80 76 98 yes no no no no no no 
35 B 26 61 154 80 65 T4 4 262 322 3 5 298 120 70 82 99 yes yes no yes no no no 
36 B 24 56 160 80 60 T6 3 250 466 4 6 260 110 76 94 98 yes yes no yes no no no 
37 M 32 62 167 84 72 T4 5 188 342 3 6 180 128 80 86 99 no no no no no no no 
38 B 28 65 160 78 60 T4 5 258 337 3 6 267 118 68 91 98 yes no no no no no no 
39 B 27 58 156 80 62 T4 2 250 480 2 6 300 120 80 76 98 yes no no no no no no 
40 M 24 58 155 78 40 T6 3 153 345 1 4 200 126 80 106 99 no no no no no no no 
41 M 31 64 160 86 65 T4 5 166 345 3 6 176 120 80 78 99 no no no no no no no 
42 M 25 58 162 80 68 T5 6 154 300 4 7 189 124 76 88 99 no no no no no no no 
43 B 29 64 156 82 65 T4 4 222 450 2 5 278 125 81 90 99 no no no no no no no 
44 B 30 61 154 80 65 T4 5 262 500 3 6 298 120 70 82 99 yes yes no yes no no no 
45 M 21 56 150 84 60 T5 5 150 310 2 5 200 116 70 97 98 no no no no no no no 
46 M 27 65 156 84 60 T4 3 158 337 1 5 186 136 80 88 99 yes no no no no no no 
47 M 25 58 148 84 64 T6 2 170 360 2 4 280 120 78 91 97 no no no no no no no 
48 M 24 56 156 80 68 T5 5 166 300 4 6 176 122 70 78 99 no no no no no no no 
49 B 21 58 159 78 65 T6 4 256 450 2 5 300 130 78 89 99 no no no no no no no 
50 B 27 58 156 80 62 T4 3 250 480 2 6 300 120 80 76 98 yes no no no no no no 
51 M 31 62 156 79 60 T5 2 155 350 3 5 272 125 81 107 98 no no no no no no no 
52 M 29 60 152 80 68 T6 5 153 300 4 6 176 120 72 78 99 yes no no yes no no no 
53 B 20 64 156 82 65 T4 4 222 450 2 5 278 125 81 90 99 no no no no no no no 
54 M 23 58 155 78 40 T6 6 153 300 1 4 200 126 80 106 99 no no no no no no no 
55 M 24 56 156 80 68 T5 5 166 300 4 6 176 132 86 78 99 no no no no no no no 
56 M 25 60 156 55 76 T6 5 150 310 2 8 180 125 67 70 98 yes no no yes no no no 
57 B 33 58 152 79 63 T6 3 163 488 2 4 287 118 74 84 99 no no no yes no no no 
58 B 28 65 160 78 60 T4 4 258 337 3 6 267 118 68 91 98 yes no no no no no no 
59 B 24 56 160 80 60 T6 5 250 466 4 6 260 110 70 94 98 yes yes no yes no no no 
60 M 24 56 156 80 68 T4 5 148 334 4 6 176 110 70 78 99 no no no no no no no 
 
